Roivant spinout Priovant reported Phase 2 data showing brepocitinib—a TYK2/JAK1 inhibitor inherited from Pfizer—significantly outperformed placebo in cutaneous sarcoidosis, registering larger‑than‑expected lesion improvements in a small trial. Investigators described the magnitude of effect as striking and suggested the result could be practice‑changing for a disease with few approved therapies. The positive readout adds momentum to Priovant’s broader effort to develop brepocitinib across rare dermatologic indications, including dermatomyositis. The program benefits from prior clinical experience and larger safety datasets, but sponsors will need controlled, larger trials to support registration in orphan and rare‑disease populations.